{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:40:09Z","timestamp":1792374009551,"version":"4.4.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0227356","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T23:06:51Z","timestamp":1578438411000},"page":"e0227356","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies"],"prefix":"10.1371","volume":"15","author":[{"given":"Alexandre","family":"Perrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Boelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gligorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Lotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Brault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comperat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lef\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6494-5722","authenticated-orcid":true,"given":"Mathieu","family":"Boissan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,1,7]]},"reference":[{"issue":"1","key":"pone.0227356.ref001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"RL Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"29","key":"pone.0227356.ref002","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2015.61.8983","article-title":"Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines","volume":"34","author":"MV Shah","year":"2016","journal-title":"J Clin Oncol"},{"key":"pone.0227356.ref003","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"DJ Slamon","year":"1987","journal-title":"Science"},{"key":"pone.0227356.ref004","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"EH Romond","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0227356.ref005","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"SM Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0227356.ref006","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1373\/clinchem.2009.135566","article-title":"Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer","volume":"56","author":"R Molina","year":"2010","journal-title":"Clin Chem"},{"issue":"3","key":"pone.0227356.ref007","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1373\/clinchem.2005.059832","article-title":"Serum tumor markers in breast cancer: are they of clinical value?","volume":"52","author":"MJ Duffy","year":"2006","journal-title":"Clin Chem"},{"issue":"1","key":"pone.0227356.ref008","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7150\/jca.13090","article-title":"Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer","volume":"7","author":"S-G Wu","year":"2016","journal-title":"J Cancer"},{"issue":"4","key":"pone.0227356.ref009","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/annonc\/mdm538","article-title":"Preoperative CA 15\u20133 and CEA serum levels as predictor for breast cancer outcomes","volume":"19","author":"B-W Park","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"pone.0227356.ref010","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/annonc\/mds604","article-title":"Elevated Levels of Preoperative CA 15\u20133 and CEA Serum Levels Have Independently Poor Prognostic Significance in Breast Cancer","volume":"24","author":"J. S. Lee","year":"2013","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"key":"pone.0227356.ref011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cca.2014.11.001","article-title":"Serum HER2 in combination with CA 15\u20133 as a parameter for prognosis in patients with early breast cancer","volume":"440","author":"D Di Gioia","year":"2015","journal-title":"Clin Chim Acta"},{"issue":"6","key":"pone.0227356.ref012","first-page":"7549","article-title":"Elevation of serum CEA and CA15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients","volume":"14","author":"Y Yang","year":"2017","journal-title":"Oncol Lett"},{"issue":"1","key":"pone.0227356.ref013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0959-8049(98)00297-4","article-title":"The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer","volume":"35","author":"JF Robertson","year":"1999","journal-title":"Eur J Cancer"},{"issue":"4","key":"pone.0227356.ref014","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF02968047","article-title":"Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study","volume":"11","author":"J Kurebayashi","year":"2004","journal-title":"Breast Cancer"},{"issue":"1","key":"pone.0227356.ref015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/bjc.1993.310","article-title":"Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?","volume":"68","author":"AR Dixon","year":"1993","journal-title":"Br J Cancer"},{"issue":"24","key":"pone.0227356.ref016","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1200\/JCO.2015.61.1459","article-title":"Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"33","author":"C Van Poznak","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0227356.ref017","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s13277-011-0180-7","article-title":"Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC)","volume":"32","author":"D Di Gioia","year":"2011","journal-title":"Tumour Biol"},{"issue":"6","key":"pone.0227356.ref018","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41374-018-0033-8","article-title":"The extracellular domain of Her2 in serum as a biomarker of breast cancer","volume":"98","author":"A Perrier","year":"2018","journal-title":"Lab Invest"},{"issue":"22","key":"pone.0227356.ref019","first-page":"5123","article-title":"NH2-terminally truncated HER-2\/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer","volume":"58","author":"TA Christianson","year":"1998","journal-title":"Cancer Res"},{"issue":"2","key":"pone.0227356.ref020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-016-4000-z","article-title":"A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression","volume":"160","author":"N Reix","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"pone.0227356.ref021","first-page":"199","article-title":"Challenges in the clinical utility of the serum test for HER2 ECD","volume":"1826","author":"L Lam","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"pone.0227356.ref022","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ctrv.2011.03.008","article-title":"HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer","volume":"38","author":"C Ts\u00e9","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"pone.0227356.ref023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/BIC.S12389","article-title":"Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?","volume":"5","author":"WP Carney","year":"2013","journal-title":"Biomark Cancer"},{"issue":"2C","key":"pone.0227356.ref024","first-page":"1261","article-title":"Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma","volume":"24","author":"MT Sandri","year":"2004","journal-title":"Anticancer Res"},{"issue":"15","key":"pone.0227356.ref025","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/cncr.28130","article-title":"Soluble HER2 (sHER2) levels in HER2-positive breast cancer patients receiving chemotherapy \u00b1 trastuzumab: Results from the NCCTG adjuvant trial N9831","volume":"119","author":"A Moreno-Aspitia","year":"2013","journal-title":"Cancer"},{"issue":"6","key":"pone.0227356.ref026","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1309\/AJCPIRL4GUVGK3YX","article-title":"HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer","volume":"142","author":"HJ Lee","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"pone.0227356.ref027","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s40064-015-1015-6","article-title":"Monitoring serum HER2 levels in breast cancer patients","volume":"4","author":"J Tchou","year":"2015","journal-title":"Springerplus"},{"key":"pone.0227356.ref028","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cca.2016.04.025","article-title":"Meaningful interpretation of serum HER2 ECD levels requires clear patient clinical background, and serves several functions in the efficient management of breast cancer patients","volume":"458","author":"T Wang","year":"2016","journal-title":"Clin Chim Acta"},{"issue":"36","key":"pone.0227356.ref029","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1200\/JCO.2009.23.4674","article-title":"Value of serum human epidermal growth factor receptor 2 (HER2)\/neu testing for early prediction of response to HER2\/neu-directed therapies is still an open one and deserves further study in large prospective trials","volume":"27","author":"SM Ali","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0227356.ref030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/annonc\/mdi059","article-title":"Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate","volume":"16","author":"MN Fornier","year":"2005","journal-title":"Ann Oncol"},{"issue":"9","key":"pone.0227356.ref031","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1200\/JCO.2015.62.4767","article-title":"Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer","volume":"34","author":"CK Lee","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"pone.0227356.ref032","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1200\/JCO.2008.17.3989","article-title":"Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients","volume":"27","author":"AF Leary","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"pone.0227356.ref033","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.2008.16.8351","article-title":"Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer","volume":"27","author":"S Lennon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0227356.ref034","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(10)70297-7","article-title":"Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls","volume":"12","author":"B Leyland-Jones","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7","key":"pone.0227356.ref035","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1515\/cclm-2012-0488","article-title":"Sensitivity of CA 15\u20133, CEA and serum HER2 in the early detection of recurrence of breast cancer","volume":"51","author":"AC Pedersen","year":"2013","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"pone.0227356.ref036","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/13547500902770090","article-title":"Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences","volume":"14","author":"L Mariani","year":"2009","journal-title":"Biomarkers"},{"key":"pone.0227356.ref037","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cca.2015.06.022","article-title":"Diagnostic efficacy of CA 15\u20133 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients","volume":"448","author":"P Stieber","year":"2015","journal-title":"Clin Chim Acta"},{"issue":"10","key":"pone.0227356.ref038","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.1986.4.10.1542","article-title":"Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer","volume":"4","author":"DF Hayes","year":"1986","journal-title":"J Clin Oncol"},{"key":"pone.0227356.ref039","first-page":"986","article-title":"Development and Evaluation of a Radioimmunoassay for the Detection of a Monoclonal Antibody Defined Breast Tumor Associated Antigen 115D8\/DF3","volume":"31","author":"R Tobias","year":"1985","journal-title":"Clin Chem"},{"issue":"2","key":"pone.0227356.ref040","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ijc.2910340210","article-title":"Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors","volume":"34","author":"J Hilkens","year":"1984","journal-title":"Int J Cancer"},{"key":"pone.0227356.ref041","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/B978-0-08-030764-0.50232-9","article-title":"Monoclonal Antibodies Against Human Milk-Fat Globule Membranes Useful in Carcinoma Research","volume":"31","author":"J Hilkens","year":"1984","journal-title":"Prot Biol Fluids"},{"issue":"3","key":"pone.0227356.ref042","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/hyb.1984.3.223","article-title":"Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors","volume":"3","author":"D Kufe","year":"1984","journal-title":"Hybridoma"},{"key":"pone.0227356.ref043","first-page":"11","article-title":"Molecular Aspects of Mucins","volume":"11\u201312","author":"J Taylor-Papadimitriou","year":"1988","journal-title":"Cancer Rev"},{"issue":"2","key":"pone.0227356.ref044","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/clinchem\/30.2.200","article-title":"Roche RIA and Abbott EIA Carcinoembryonic Antigen Assays Compared","volume":"30","author":"M. Fleisher","year":"1984","journal-title":"Clinical Chemistry"},{"key":"pone.0227356.ref045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/clinchem\/46.2.175","article-title":"Automated assay for HER-2\/neu in serum","volume":"46","author":"RC Payne","year":"2000","journal-title":"Clin Chem"},{"key":"pone.0227356.ref046","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/172460080401900301","article-title":"ADVIA Centaur HER-2\/neu shows value in monitoring patients with metastatic breast cancer","volume":"19","author":"D Luftner","year":"2004","journal-title":"Int J Biol Markers"},{"issue":"4","key":"pone.0227356.ref047","doi-asserted-by":"crossref","first-page":"R436","DOI":"10.1186\/bcr1020","article-title":"Clinical utility of serum HER2\/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies","volume":"7","author":"FJ Esteva","year":"2005","journal-title":"Breast Cancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T18:02:19Z","timestamp":1613412139000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227356"}},"subtitle":[],"editor":[{"given":"Sandro","family":"Pasquali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,7]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0227356","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,7]]}}}